Previous 10 | Next 10 |
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7 th Annual Jefferies Cell Therapy Virtual Summit on Octob...
– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva – – Doug Pagán Steps Down from Board of Directors – BOSTON, Sept. 22, 2020 (GLOBE N...
BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB, under the leadership of Carl June, M.D...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) were zooming 13.1% higher as of 3:50 p.m. EDT on Monday. The big jump came after the company announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (also known as Control...
The FDA has granted Rare Pediatric Disease Designation to Ziopharm Oncology's ( ZIOP ) veledimex (Controlled IL-12) with Ad-RTS-hIL-12, for the treatment of diffuse intrinsic pontine glioma (DIPG), a type of brain tumor occurring in the pontine region of the brain (acts as a...
BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Con...
BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences: To access the live webcast presentations, or the subsequen...
Image source: The Motley Fool. Ziopharm Oncology Inc (NASDAQ: ZIOP) Q2 2020 Earnings Call Aug 6, 2020 , 4:30 p.m. ET Operator Continue reading
ZIOPHARM Oncology, Inc. (ZIOP) Q2 2020 Earnings Conference Call August 6, 2020 4:30 p.m. ET Company Participants Chris Taylor - VP, IR and Corporate Communications Laurence Cooper - CEO Sath Shukla - CFO Conference Call Participants Chris Howerton - Jeffries Thomas Flaten...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...